Transdermal delivery of timolol maleate using hydrogel microneedles for the treatment of infantile haemangiomas

IF 8.7 1区医学 Q1 ENGINEERING, BIOMEDICAL

Materials Today Bio Pub Date : 2025-04-12 DOI:10.1016/j.mtbio.2025.101752

Xiaokun Lin , Tongshuai Kuang , Lei Wang , Wei Cai , Linxing Yang , Changrong Guo , Xinyang Pan , Yuanhao Wang , Qiang Gao , Kaihui Nan , Lingli Li

{"title":"Transdermal delivery of timolol maleate using hydrogel microneedles for the treatment of infantile haemangiomas","authors":"Xiaokun Lin , Tongshuai Kuang , Lei Wang , Wei Cai , Linxing Yang , Changrong Guo , Xinyang Pan , Yuanhao Wang , Qiang Gao , Kaihui Nan , Lingli Li","doi":"10.1016/j.mtbio.2025.101752","DOIUrl":null,"url":null,"abstract":"<div><div>Infantile haemangioma (IH), the most prevalent vascular tumour in infants, requires early intervention because of the potential complications in critical areas such as the head and face. Current treatments, including topical timolol maleate (TIM), face challenges such as poor compliance, low drug utilisation, and lengthy treatment durations. In this study, we developed a hydrogel microneedle (MN) using photocurable bovine serum albumin methacryloyl (BSAMA) as a carrier for TIM. Our results showed the controlled release of TIM from BSAMA-TIM MNs, with approximately 69 % release ratio within 72 h. <em>In-vivo</em> studies on nude mice demonstrated that BSAMA-TIM-MNs inhibited the growth of haemangioma xenografts. Our TIM-delivering MNs exhibited high therapeutic efficacy, minimal cytotoxicity, and reduced dosing frequency. In conclusion, BSAMA-TIM MNs provide a promising strategy for treating IH.</div></div>","PeriodicalId":18310,"journal":{"name":"Materials Today Bio","volume":"32 ","pages":"Article 101752"},"PeriodicalIF":8.7000,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Materials Today Bio","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590006425003126","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Infantile haemangioma (IH), the most prevalent vascular tumour in infants, requires early intervention because of the potential complications in critical areas such as the head and face. Current treatments, including topical timolol maleate (TIM), face challenges such as poor compliance, low drug utilisation, and lengthy treatment durations. In this study, we developed a hydrogel microneedle (MN) using photocurable bovine serum albumin methacryloyl (BSAMA) as a carrier for TIM. Our results showed the controlled release of TIM from BSAMA-TIM MNs, with approximately 69 % release ratio within 72 h. In-vivo studies on nude mice demonstrated that BSAMA-TIM-MNs inhibited the growth of haemangioma xenografts. Our TIM-delivering MNs exhibited high therapeutic efficacy, minimal cytotoxicity, and reduced dosing frequency. In conclusion, BSAMA-TIM MNs provide a promising strategy for treating IH.

Abstract Image

查看原文本刊更多论文

水凝胶微针经皮给药马来酸替洛尔治疗婴儿血管瘤

婴儿血管瘤（IH）是婴儿中最常见的血管肿瘤，由于头部和面部等关键部位的潜在并发症，需要早期干预。目前的治疗方法，包括外用马来酸噻洛尔（TIM），面临着诸如依从性差、药物利用率低和治疗持续时间长等挑战。在这项研究中，我们开发了一种水凝胶微针（MN），以光固化牛血清白蛋白甲基丙烯酰（BSAMA）为载体。我们的研究结果显示，BSAMA-TIM MNs的TIM释放可控，在72小时内释放率约为69%。裸鼠体内研究表明，BSAMA-TIM-MNs抑制异种血管瘤的生长。我们的tim递送MNs表现出高的治疗效果、最小的细胞毒性和较低的给药频率。总之，BSAMA-TIM MNs为治疗IH提供了一个有希望的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Materials Today Bio Multiple-

CiteScore

8.30

自引率

4.90%

发文量

303

审稿时长

30 days

期刊介绍： Materials Today Bio is a multidisciplinary journal that specializes in the intersection between biology and materials science, chemistry, physics, engineering, and medicine. It covers various aspects such as the design and assembly of new structures, their interaction with biological systems, functionalization, bioimaging, therapies, and diagnostics in healthcare. The journal aims to showcase the most significant advancements and discoveries in this field. As part of the Materials Today family, Materials Today Bio provides rigorous peer review, quick decision-making, and high visibility for authors. It is indexed in Scopus, PubMed Central, Emerging Sources, Citation Index (ESCI), and Directory of Open Access Journals (DOAJ).